Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment

Enrique Grande, R. Donald Harvey, Benoit You, Jaime Feliu Batlle, Hal Galbraith, John Sarantopoulos, Suresh S. Ramalingam, Helen Mann, Karen So, Martin Johnson, Karthick Vishwanathan

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of mild and moderate hepatic impairment on the pharmacokinetics (PK) of osimertinib in patients with malignant solid tumors. In part A, patients with normal hepatic function, mild hepatic impairment, and moderate hepatic impairment, according to the Child-Pugh classification, received a single 80 mg oral dose of osimertinib. Standard PK measures were assessed. In part B, patients could continue osimertinib treatment if deemed clinically appropriate. We compared these study results with a population PK analysis including other osimertinib clinical studies. Geometric mean osimertinib plasma concentrations were lower in patients with mild (n 5 7) or moderate hepatic impairment (n 5 5) versus normal hepatic function (n 5 10): Cmax was reduced to 51% and 61%, respectively; area under the curve was reduced to 63% and 68%, respectively. PK results for the metabolites were similar. No apparent differences in the safety profile were found between patients with normal hepatic function and patients with mild or moderate hepatic impairment. Comparison of these study results with National Cancer Institute-Organ Dysfunction Working Group criteria from population PK analysis showed osimertinib exposure was not affected by hepatic impairment. No dose adjustment is required for osimertinib when treating patients with mild or moderate hepatic impairment. No apparent differences in the safety of osimertinib were found between patients with normal hepatic function and mild or moderate hepatic impairment.

Original languageEnglish (US)
Pages (from-to)291-299
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume369
Issue number2
DOIs
StatePublished - May 2019

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of 'Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment'. Together they form a unique fingerprint.

Cite this